Clinical Trial Update: A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating enzastaurin plus temozolomide with/without a novel biomarker in newly diagnosed glioblastoma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Enzastaurin (enzastaurin)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Denovo Biopharma LLC | Conditions: Glioblastoma | Phase 3 | Status: COMPLETED